SUBSCRIBE
SUBSCRIBE

Biogen

NEWS
Investor
Biotech Bay
7 Hot Biotech Investing Bets
We now turn to six MoneyShow.com contributors for their best ideas in biotechnology, a sector with both high risk and the potential for high rewards.
December 20, 2017
 · 
1 min read
Deals
Bristol-Myers Who? Why a Marriage Between Pfizer and Biogen Makes More Sense
Investors love to speculate on M&A, and one of the hottest topics of speculation recently has been whether someone will buy BMS.
November 14, 2017
 · 
3 min read
 · 
Mark Terry
Gemini Therapeutics Banks $42.5M to Bring Precisio
Biotech Bay
Top 5 Best Biotechs That Could Beat Estimates in Q3
The Q3 earnings season is approaching its end with 81.2% of the S&P 500 companies having already released results.
November 8, 2017
 · 
1 min read
Drug Development
Biogen’s Early-Stage Alzheimer’s Data Continues to Impress
ALZ’s researchers continue to see hope in Biogen’s aducanumab.
November 2, 2017
 · 
2 min read
 · 
Alex Keown
3 Biotechs That Got Huge Boosts From Spark's FDA P
Business
Why Even Spinraza Can’t Save Biogen’s Incoming MS Meltdown
Biogen released its third-quarter financials yesterday, showing total revenues of $3.1B for the quarter, a 4 percent gain compared to the same period the previous year.
October 25, 2017
 · 
4 min read
 · 
Mark Terry
Small Cambridge Biotech Warp Bio Scores $387M R&D
Business
Biogen Throws Another $200M at Aducanumab With Amended Deal With Neurimmune
Despite the failures of late stage ALZ’s drugs developed by numerous companies, Biogen seems confident in the future of its amyloid plaque targeting aducanumab.
October 24, 2017
 · 
2 min read
 · 
Alex Keown
Genetown
Biogen And Celgene: Which Is The Better Buy Right Now?
October 10, 2017
 · 
1 min read
Drug Development
Biogen’s Alzheimer’s Pipeline Gets Some More Love
October 6, 2017
 · 
1 min read
Drug Development
A Frustrating Quest: Why Biogen Could Be Our Best Hope For Alzheimer’s Right Now
September 28, 2017
 · 
1 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
JOBS
IN THE PRESS
Press Releases
The ADDF Highlights Encouraging Progress Toward Targeting Multiple Alzheimer’s Pathologies in Biogen’s Phase 2 Tau Study
May 14, 2026
 · 
3 min read
Press Releases
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease
May 14, 2026
 · 
8 min read
Press Releases
Biogen Completes Acquisition of Apellis Pharmaceuticals
May 14, 2026
 · 
21 min read
Press Releases
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
May 14, 2026
 · 
11 min read
Press Releases
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease
May 8, 2026
 · 
18 min read
Press Releases
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
April 20, 2026
 · 
14 min read
Press Releases
Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer’s Disease at the 78th American Academy of Neurology’s Annual Meeting
April 9, 2026
 · 
10 min read
Press Releases
Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform
April 7, 2026
 · 
3 min read
Press Releases
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
March 31, 2026
 · 
32 min read
Press Releases
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
March 30, 2026
 · 
13 min read
Load More